Today: 3 April 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Edinburgh Hogmanay power cuts: Grassmarket pubs warn blackouts could hit New Year rush

Edinburgh Hogmanay power cuts: Grassmarket pubs warn blackouts could hit New Year rush

Repeated power outages hit Edinburgh’s Grassmarket on Dec. 30 and 31, disrupting festive trade as venues prepared for Hogmanay, operators said. SP Energy Networks blamed an intermittent fault and said extra staff were on standby. Businesses reported lost bookings and wasted stock, with some venues losing entire peak services. Operators urged the council and network to publish plans for upgrades and contingency measures.
1 January 2026
·
Visa stock today: $500 million escrow move reshapes share conversion math as markets shut

Visa stock today: $500 million escrow move reshapes share conversion math as markets shut

Visa lowered conversion rates for its class B-1 and B-2 shares after a $500 million litigation escrow deposit, according to a regulatory filing. The changes, effective Dec. 23, reduce the number of class A shares issued if conversion occurs. Visa shares closed down 0.8% at $350.71 ahead of the New Year holiday. The company has not set a date for its next earnings report.
1 January 2026
·
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics shares fell 50.4% to $34.80 after the FDA declined to approve relacorilant for Cushing’s-related hypertension, citing a need for more evidence of effectiveness. The company plans to meet with the agency to discuss next steps. Wolfe Research downgraded the stock and removed projected sales for the indication. Trading volume reached about 20.16 million shares.
1 January 2026
··
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome Therapeutics shares surged 22.9% to $182.64 after the FDA granted priority review to its application for AXS-05 in treating agitation in Alzheimer’s disease, setting an April 30 decision date. The company also plans to file for approval of AXS-12 for cataplexy in narcolepsy this month, following supportive FDA meeting minutes. Trading volume reached 3.1 million shares.
1 January 2026
··
INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

Intelligent Bio Solutions shares jumped 132% to $9.53 before dropping 14% after-hours as the company announced a $10 million private placement and a new manufacturing deal with Syrma Johari MedTech. The placement, priced at $4.35 per share and warrants, is set well below the closing price. Volume hit 108 million shares. The company recently enacted a 1-for-10 reverse split after a Nasdaq minimum bid warning.
1 January 2026
··
Nike stock jumps on CEO’s $1 million buy — what NKE investors watch next

Nike stock jumps on CEO’s $1 million buy — what NKE investors watch next

Nike shares rose 4.1% to $63.71 in the final 2025 session after CEO Elliott Hill bought 16,388 shares for about $1 million, according to an SEC filing. The gain came as Wall Street closed the year lower and Under Armour shares fell 3%. Trading volumes were thin ahead of the New Year’s Day market holiday. Investors are watching for updates on Nike’s margins and China demand as earnings approach.
1 January 2026
·
Ford stock today: F slips in thin year-end session as traders eye insider filing and Feb. 10 earnings

Ford stock today: F slips in thin year-end session as traders eye insider filing and Feb. 10 earnings

Ford Motor shares slipped 0.6% to $13.16 in thin year-end trading Wednesday, with about 16.5 million shares changing hands. A Form 4 filing showed Executive Chair William Clay Ford Jr. and director Alexandra Ford English made gifts and transfers of Class B stock at $0 per share on Dec. 22. General Motors, Stellantis, and Tesla also traded lower. Ford will report Q4 and full-year results on Feb. 10.
31 December 2025
··
Sunrun stock drops today as Treasury yields tick higher in year-end trading

Sunrun stock drops today as Treasury yields tick higher in year-end trading

Sunrun Inc. shares dropped 3.8% to $18.37 in afternoon trading Wednesday, tracking declines across solar stocks as U.S. Treasury yields edged higher. The stock traded between $18.34 and $19.20, with little company-specific news. Sunrun last announced a partnership with NRG Energy on Dec. 16. Investors are watching labor data and interest rates for further signals.
31 December 2025
··
BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

BillionToOne shares fell 4% to $81.61 in thin trading on the last day of 2025, underperforming diagnostics peers. The company last reported third-quarter revenue of $83.5 million, up 117% year over year, and forecast full-year revenue of $293 million to $299 million. No new company disclosures appeared Wednesday. Management is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
31 December 2025
··
Why Super Micro (SMCI) stock is down today: an exec retirement filing meets year-end AI trade

Why Super Micro (SMCI) stock is down today: an exec retirement filing meets year-end AI trade

Super Micro Computer shares fell 1.7% to $29.15 after a filing showed Senior VP of Operations George Kao will retire Dec. 31, with Tom Xiao set to replace him. The company said Kao will help with the transition as a consultant. The move came as investors watched AI infrastructure spending, highlighted by xAI’s purchase of a third building to expand compute capacity. Major U.S. indexes drifted lower in thin holiday trading.
31 December 2025
····
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics shares climbed 3.7% to $63.63 Wednesday, bucking a weaker market as investors awaited Myqorzo’s U.S. launch in January. A Form 4 showed Chief Commercial Officer Andrew Callos sold 1,809 shares at $62.44 on Dec. 29 under a pre-set plan. The drug, approved this month, will be distributed with a REMS safety program. Investors are watching for pricing details and initial uptake.
31 December 2025
··
1 … 329 330 331 332 333 … 584

Stock Market Today

  • Agenus (AGEN) Shares Poised for Gains on Upward Earnings Estimate Revisions
    April 3, 2026, 2:04 PM EDT. Agenus (AGEN) has seen analysts markedly raise earnings forecasts, signaling growing optimism for the biotech firm. The consensus estimate for the current quarter jumped 289.3% to $1.95 per share, while full-year estimates increased by 151.8% to $1.30 per share. This momentum fueled a 14% stock rise in the past month. Agenus holds a Zacks Rank #1 (Strong Buy), reflecting strong correlations between earnings estimate revisions and stock price moves. Investors may find Agenus a compelling buy as estimates continue improving and stock gains persist.
Go toTop